Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.44 |
| ▸ | GRK6 | P43250 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084647 | 0.88 | CLK2 (0.46) | LRRK2CHEK1TTKITKCDK7 | |
| SCHEMBL4085679 | 0.87 | LRRK2 (0.42) | LRRK2GRK6TTKITKCLK2 | |
| SCHEMBL4084381 | 0.86 | GSK3B (0.46) | LRRK2GRK6ITKALDH1A1LMNA | |
| SCHEMBL13811890 | 0.81 | GRK6 (0.46) | LRRK2GRK6TTKITKPRKAG1 | |
| SCHEMBL4089492 | 0.79 | TTK (0.46) | LRRK2CHEK1GRK6TTKITK | |
| SCHEMBL13811889 | 0.79 | HRH3 (0.43) | LRRK2ITKCLK2GSK3B | |
| SCHEMBL13812149 | 0.79 | LRRK2 (0.39) | LRRK2GRK6TTKITKGAA | |
| SCHEMBL13812153 | 0.79 | GSK3B (0.47) | LRRK2TTKCLK2GSK3B | |
| SCHEMBL4083131 | 0.79 | CSNK1D (0.45) | CLK2GSK3B | |
| SCHEMBL5817740 | 0.78 | CSNK1D (0.46) | CLK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | LRRK2 553/4885CHEK1 322/4885GRK6 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.